Levien 35. Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis. Arthritis Rheum. 1998;41:670–677. 36. Belch JJ, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynaud’s syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis. 1995;54:197–200. 37. Black CM, Halkier-Sorensen L, Belch JJF, et al. Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol. 1998; 37:952–960. 38. Pakozdi A, Howell K, Wilson H, et al. Inhaled iloprost for the treatment of Raynaud’s phenomenon. [abstract]American College of Rheumatology 2007 Annual Meeting. Boston, MA: November 6–11, 2007; abstract 1225. 39. Bartolone S, Trifiletti A, De Nuzzo G, et al. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud’s phenomenon. Minerva Cardioangiol. 1999;47:137–143. 40. Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud’s syndrome. Ann Rheum Dis. 1985;44:754–760. 41. Vayssairat M. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud’s phenomenon. J Rheumatol. 1996;23:1917–1920. 42. Korn JH, Mayes M, Cerinic MM, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985–3993. 43. Black C, Denton CP, Furst DE, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis – open label extension to a double-blind trial [abstract]. Ann Rheum Dis. 2006; 65(Suppl 2):384. 44. Seibold JR, Denton CP, Furst DE, et al. Bosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis (SSc) [abstract]. Annual Meeting of the American College of Rheumatology 2005; abstract L2. 45. Sfikakis PP, Papamichael C, Stamatelopoulos KS, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007;56:1985–1993. 46. Tsifetaki N, Botzoris VG, Argyriou E, Drosos AA. Bosentan for digital ulcers in patients with systemic sclerosis. A prospective 3-year follow-up study [abstract]. American College of Rheumatology 2008 Annual Scientific Meeting; abstract 1785. 47. Garcia de la Pena-Lefebvre P, Rubio SR, Exposito MV, et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology. 2008;47:464–466. 48. Launay D, Diot E, Pasquier E, et al. Bosentann for treatment of active digital ulcers in patients with systemic sclerosis (9 cases). Presse Med. 2006;35:587–592. 49. Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud’s phenomenon with the endothelial receptor antagonist bosentan. Rheumatology. 2006;45:iii45–iii48. 50. Funauchi M, Kishimoto K, Shimazu H, et al. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol Int. 2009;29:769–775. 51. Hettema ME, Zhang D, Bootsma H, Kallenberg CGM. Bosentan therapy for patients with severe Raynaud’s phenomenon in systemic sclerosis [letter]. Ann Rheum Dis. 2007;66:1398–1399. 52. Ramos-Casals M, Brito-Zeron P, Nardi N, et al. Successful treatment of severe Raynaud’s phenomenon with bosentan in four patients with systemic sclerosis [letter]. Rheumatology. 2004;43:1454–1456. 53. Dunne J, Dutz J, Shojania K, Ng B, van Elden S. Treatment of severe Raynaud’s phenomenon with bosentan in a patient with systemic scle- rosis [letter]. Rheumatology. 2006;45:911–912. 54. Moore TL, Vail A, Herrick AL. Assessment of digital vascular struc- ture and function in response to bosentan in patients with systemic sclerosis-related Raynaud’s phenomenon [letter]. Rheumatology. 2007;46:363–364. 176 submit your manuscript | www.dovepress.com Dovepress Dovepress 55. Halcox JPJ, Nour KRA, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002;40:1232–1240. 56. Watanabe H, Nishio S, Ohmae E, et al. Sildenafil improves forearm blood flow in patients with Raynauds phenomenon [abstract]. Eur Heart J. 2004;25(Suppl.):202. 57. Carlino G. Treatment of Raynaud’s phenomenon with tadalafil, a phosphodiesterase-5 inhibitor [abstract]. Ann Rheum Dis 2005;64 (Suppl 3):258. 58. Zamiri B, Koman AL, Smith BP, et al. Double-blind, placebo-controlled trial of sildenafil for the management of primary Raynaud’s phenomenon [abstract]. Ann Rheum Dis. 2004;63(Suppl. 1):484–485. 59. ShenoyP, Agarwal V, Kumar S, et al. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double- blind randomized cross-over trial [abstract]. Arthritis Rheum. 2008; 58(9 Suppl):S402. 60. Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, et al. Randomized placbo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36:2264–2268. 61. Pakozdi A, Howell K, Black CM, Denton CP. Addition of the short term phosphodiesterase-5 inhibitor sildenafil to iloprost therapy for scleroderma digital vasculopathy [abstract]. ACR/ARHP Scientific Meeting 2007. Boston, MA: November 6–11, 2007; abstract 2167. 62. Abeles M, Abeles AM. Phosphodiesterase inhibitor tadalafil in the treatment of ischemic digital ulcers/digital necrosis due to scleroderma- associated Raynaud’s phenomenon [abstract]. Arthritis Rheum. 2008; 58(9 Suppl):S822. 63. Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med. 2006;166:231–233. 64. Kumar N, Griffiths B, Allen J. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud’s phenomenon in patients with systemic sclerosis: a potential treatment [letter]. J Rheumatol. 2006;33(9):1918–1919. 65. Becker M, Bruckner CS, Scherer H, Burmester GR, Riemekasten G. Effect of sildenafil on digital ulcers in systemic sclerosis – analysis from a single centre study [abstract]. Ann Rheum Dis. 2009;68(Suppl 3):96. 66. Brueckner C, Scherer U, Burmester G, Becker MO, Dragun D, Riemekasten G. Effect of sildenafil on healing of digital ulcers in patients with systemic sclerosis [abstract]. Ann Rheum Dis. 2008; 67(Suppl 2):362. 67. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud’s phe- nomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis. 2005;64:1387. 68. Baak SW. Treatment of Raynaud’s phenomena with the PDE-5 inhibitor, Cialis (tadalafil) in patients with scleroderma and lupus [abstract]. Arthritis Rheum. 2005;52(9 Suppl.):S169. 69. Lichtenstein JR. Use of sildenafil citrate in Raynaud’s phenomenon: comment on the article by Thompson et al. [letter] Arthritis Rheum. 2003;48:282–283. 70. Cheung GTY, Lau CS, Kumana CR. Phosphodiesterase-5 inhibitors relieve symptoms of severe Raynaud’s phenomenon [abstract]. Ann Rheum Dis. 2004;63(Suppl 1):313. 71. Kumana CR, Cheung GTY, Lau CS. Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis. 2004;63:1522–1524. 72. Colglazier CL, Sutej PG, O’Rourke KS. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol. 2005;32:2440–2442. 73. Baumhaekel M, Scheffler P, Boehm M. Use of tadalafil in a patient with a secondary Raynaud’s phenomenon not responding to sildenafil. Microvascular Res. 2005;69:178–179. 74. Kropman RF. Raynaud’s phenomenon of the penis. J Urol. 2004;171:1630. 75. Kamata Y, Kamimura T, Iwamoto M, Minota S. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud’s phenomenon in a patient with systemic sclerosis. Clin Exp Dermatol. 2005;30:451. Vascular Health and Risk Management 2010:6